Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial
Journal Title: Annals of Hepatology - Year 2009, Vol 8, Issue 1
Abstract
It is a comment of an article published in N Engl J Med. 2008;359:2429-41
Authors and Affiliations
Mazhar Haque, Eric Yoshida
Keywords
Related Articles
- EP ID EP77835
- DOI -
- Views 134
- Downloads 0
IGF-I and IGFBP-3 serum levels in patients hospitalized for complications of liver cirrhosis
[b]Background[/b]. IGF-I and IGFBP-3 are part of IGF system and, due to their predominantly hepatic synthesis, they seem to correlate with hepatic dysfunction intensity. Aims. To investigate the significance of IGF-I and...
Current and future treatment options for HCV
Aim of antiviral therapy of patients with chronic hepatitis C is the sustained elimination of the hepatitis C virus (HCV). The standard of care (SOC) is peginterferon alfa-2a/-2b with ribavirin for 48 weeks or 24 weeks i...
Prediction of poor graft function by means of gastric tonometry in patients undergoing liver transplantation
Introduction. Splanchnic hypoperfusion appears to play a key role in the failure of functional recovery of the graft after orthotopic liver transplantation (LT). The aim of this study was to determine if alterations of t...
Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant
Background and aims. Pegylated interferon (Peg-INF) and ribavirin (RBV) based therapy is suboptimal and poorly tolerated. We evaluated the safety, tolerability and efficacy of a 24-week course of sofosbuvir plus daclata...
Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjögren’s syndrome
Background/Aims: Patients with primary Sjögren’s syndrome may present liver involvement. Our goals were to establish the prevalence of abnormal hepatic biochemistries and clinical liver disease in patients with primary S...